Changes: Lipinski's Rule of 5

Latest revision as of 23:58, 21 December 2007

Biological: Behavioural genetics · Evolutionary psychology · Neuroanatomy · Neurochemistry · Neuroendocrinology · Neuroscience · Psychoneuroimmunology · Physiological Psychology · Psychopharmacology (Index, Outline)

It has been suggested that this article or section be merged into [[::Druglikeness|Druglikeness]]. (Discuss)

Lipinski's Rule of Five is a rule of thumb to evaluate druglikeness, or determine if a chemical compound with a certain pharmacological or biological activity has properties that would make it a likely orally active drug in humans. The rule was formulated by Christopher A. Lipinski in 1997, based on the observation that most medication drugs are relatively small and lipophilic molecules.^[1]

The rule describes molecular properties important for a drug's pharmacokinetics in the human body, including their absorption, distribution, metabolism, and excretion ("ADME"). However, the rule does not predict if a compound is pharmacologically active.

The rule is important for drug development where a pharmacologically active lead structure is optimized step-wise for increased activity and selectivity, as well as drug-like properties as described by Lipinski's rule. The modification of the molecular structure often leads to drugs with higher molecular weight, more rings, more rotatable bonds, and a higher lipophilicity.^[2]

The rule

Lipinski's Rule of Five states that, in general, an orally active drug has:

Not more than 5 hydrogen bond donors (OH and NH groups)
Not more than 10 hydrogen bond acceptors (notably N and O)
A molecular weight under 500 g/mol
A partition coefficient log P less than 5

Note that all numbers are multiples of five, which is the origin of the rule's name.

Improvements

To evaluate druglikeness better, the rules have spawned many extensions, for example one from a 1999 paper by Ghose et al.:^[3]

Partition coefficient log P in -0.4 to +5.6 range
Molar refractivity from 40 to 130
Molecular weight from 160 to 480
Number of heavy atoms from 20 to 70

Over the past decade Lipinski's profiling tool for druglikeness has led to further investigations by scientists to extend profiling tools to lead-like properties of compounds in the hope that a better starting point in early discovery can save time and cost.

References

↑
C. A. Lipinski, F. Lombardo, B. W. Dominy, P. J. Feeney, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, Adv. Drug Del. Rev., 2001, 46, 3-26. (
1. REDIRECT Template:Doi
)
↑ T. I. Oprea, A. M. Davis, S. J. Teague, P. D. Leeson, Is There a Difference between Leads and Drugs? A Historical Perspective, J. Chem. Inf. Comput. Sci., 2001, 41, 1308-1315.
↑
Arup K. Ghose, Vellarkad N. Viswanadhan, and John J. Wendoloski, A Knowledge-Based Approach in Designing Combinatorial or Medicinal Chemistry Libraries for Drug Discovery, J. Combin. Chem., 1999, 1, 55-68. (
1. REDIRECT Template:Doi
)

External links

Interactive Rule of Five calculator
Free online calculations of Hydrogen bond donor/acceptor, mass and logP using ChemAxon's Marvin and Calculator Plugins - requires Java]]

This page uses Creative Commons Licensed content from Wikipedia (view authors).

[1] C. A. Lipinski, F. Lombardo, B. W. Dominy, P. J. Feeney, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, Adv. Drug Del. Rev., 2001, 46, 3-26. (
REDIRECT Template:Doi
)

[2] REDIRECT Template:Doi

[2] T. I. Oprea, A. M. Davis, S. J. Teague, P. D. Leeson, Is There a Difference between Leads and Drugs? A Historical Perspective, J. Chem. Inf. Comput. Sci., 2001, 41, 1308-1315.

[3] Arup K. Ghose, Vellarkad N. Viswanadhan, and John J. Wendoloski, A Knowledge-Based Approach in Designing Combinatorial or Medicinal Chemistry Libraries for Drug Discovery, J. Combin. Chem., 1999, 1, 55-68. (
REDIRECT Template:Doi
)

[5] REDIRECT Template:Doi

[6] REDIRECT Template:Doi

[7] REDIRECT Template:Doi

[1]

[2]

[3]

@@ Line 2: / Line 2: @@
 {{Mergeto|Druglikeness|date=April 2007}}
-'''Lipinski's Rule of Five''' is a [[rule of thumb]] to evaluate [[druglikeness]], or determine if a [[chemical compound]] with a certain [[pharmacology|pharmacological]] or [[biological activity]] has properties that would make it a likely [[oral activity|orally active]] [[drug]] in humans. The rule was formulated by [[Christopher A. Lipinski]] in 1997, based on the observation that most [[medication]] drugs are relatively small and [[lipophilicity|lipophilic]] [[molecule]]s.<ref>C. A. Lipinski, F. Lombardo, B. W. Dominy, P. J. Feeney, ''Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings'', Adv. Drug Del. Rev., '''2001''', ''46'', 3-26. ({{DOI|10.1016/S0169-409X(00)00129-0}})</ref>
+'''Lipinski's Rule of Five''' is a rule of thumb to evaluate [[druglikeness]], or determine if a [[chemical compound]] with a certain [[pharmacology|pharmacological]] or [[biological activity]] has properties that would make it a likely [[oral activity|orally active]] [[drug]] in humans. The rule was formulated by Christopher A. Lipinski in 1997, based on the observation that most [[medication]] drugs are relatively small and [[lipophilicity|lipophilic]] [[molecule]]s.<ref>C. A. Lipinski, F. Lombardo, B. W. Dominy, P. J. Feeney, ''Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings'', Adv. Drug Del. Rev., '''2001''', ''46'', 3-26. ({{DOI|10.1016/S0169-409X(00)00129-0}})</ref>
 The rule describes [[molecular property|molecular properties]] important for a drug's [[pharmacokinetics]] in the human body, including their [[absorption (pharmacokinetics)|absorption]], [[distribution (pharmacology)|distribution]], [[metabolism]], and [[excretion]] ("[[ADME]]"). However, the rule does not predict if a compound is pharmacologically active.